Soyka Michael, Kranzler Henry R, Hesselbrock Victor, Kasper Siegfried, Mutschler Jochen, Möller Hans-Jürgen
a Psychiatric Hospital Meiringen , Meiringen , Switzerland.
b Department of Psychiatry , Ludwig-Maximilians-University , Munich , Germany.
World J Biol Psychiatry. 2017 Mar;18(2):86-119. doi: 10.1080/15622975.2016.1246752. Epub 2016 Dec 23.
These practice guidelines for the biological treatment of alcohol use disorders are an update of the first edition, published in 2008, which was developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). For this 2016 revision, we performed a systematic review (MEDLINE/PUBMED database, Cochrane Library) of all available publications pertaining to the biological treatment of alcoholism and extracted data from national guidelines. The Task Force evaluated the identified literature with respect to the strength of evidence for the efficacy of each medication and subsequently categorised it into six levels of evidence (A-F) and five levels of recommendation (1-5). Thus, the current guidelines provide a clinically and scientifically relevant, evidence-based update of our earlier recommendations. These guidelines are intended for use by clinicians and practitioners who evaluate and treat people with alcohol use disorders and are primarily concerned with the biological treatment of adults with such disorders.
这些酒精使用障碍生物治疗实践指南是2008年出版的第一版的更新版本，第一版由国际生物精神病学协会世界联合会（WFSBP）的一个特别工作组制定。对于本次2016年修订，我们对所有与酒精中毒生物治疗相关的可用出版物进行了系统评价（MEDLINE/PUBMED数据库、Cochrane图书馆），并从国家指南中提取了数据。特别工作组根据每种药物疗效证据的强度对已识别的文献进行了评估，随后将其分为六个证据级别（A-F）和五个推荐级别（1-5）。因此，本指南为我们早期的建议提供了与临床和科学相关的、基于证据的更新。这些指南供评估和治疗酒精使用障碍患者的临床医生和从业者使用，主要关注患有此类障碍的成年人的生物治疗。
